Loading
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$0.90
+$0.0068 · +0.76%
Gelteq Limited, established in 2017 and based in Caulfield, Australia, specializes in creating and commercializing advanced gel-based delivery methods for both human and animal use. The company offers customizable, white-label gel formulations that can be applied to a broad array of goods, such as prescribed pharmaceuticals, non-prescription remedies, nutritional supplements (including sports-related products), and veterinary care items.
Previous close
$0.90
+$0.0068 · +0.76%
Regular session · ET · Market data may be delayed.
Gelteq Limited, established in 2017 and based in Caulfield, Australia, specializes in creating and commercializing advanced gel-based delivery methods for both human and animal use. The company offers customizable, white-label gel formulations that can be applied to a broad array of goods, such as prescribed pharmaceuticals, non-prescription remedies, nutritional supplements (including sports-related products), and veterinary care items.
Day range
Current $0.90
52-week range
Current $0.90
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Sell
Trim exposure — unfavorable risk-reward
Valuation
23
Expensive
Sentiment
53
Mixed
Risk
63
High Risk
Momentum
18
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Gelteq Limited, established in 2017 and based in Caulfield, Australia, specializes in creating and commercializing advanced gel-based delivery methods for both human and animal use. The company offers customizable, white-label gel formulations that can be applied to a broad array of goods, such as prescribed pharmaceuticals, non-prescription remedies, nutritional supplements (including sports-related products), and veterinary care items.
Day range
Current $0.90
52-week range
Current $0.90
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 165.65K USD | — | 79.84K USD | 147.54K USD | — |
| Cost of goods sold | — | — | 48.93K USD | 94.87K USD | — |
| Gross profit | 165.65K USD | — | 30.92K USD | 52.66K USD | — |
| Research and development | 628.61K USD | 276.06K USD | 665.04K USD | 529.02K USD | 277.06K USD |
| Selling, general, and administrative | 2.22M USD | 1.27M USD | 1.7M USD | 1.55M USD | 463.73K USD |
| Operating expenses | 5.66M USD | 2.95M USD | 3.13M USD | 3.25M USD | 647.62K USD |
| Interest expense | 1.89M USD | 585.12K USD | 403.52K USD | 174.5K USD | 1.3K USD |
| Depreciation and amortization | 1.22M USD | 1.21M USD | 1.23M USD | 1.22M USD | 57.95K USD |
| Operating income | −5.5M USD | −2.95M USD | −3.1M USD | −3.19M USD | −647.62K USD |
| Net income | −6.65M USD | −3.55M USD | −3.51M USD | −3.37M USD | −648.92K USD |
Company facts updated Sep 6, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
